Abstract 453P
Background
In terms of the clinical outcome and bad prognosis of cancer, the elevation in IL-6 levels is correlated with disease progression. It is believed that the post-vaccination effect increases the levels of IL-6 antagonists, which can slow the growth of cancer cells.
Methods
This research was conducted out on all cancer patients at Dr. Moewardi General Hospital using an observational analytical research design with a cross-sectional study, with a total sample of 120 patients who were divided into groups that had and had not received vaccination. IL-6 levels were measured using blood samples. To identify the correlation between IL-6 levels and COVID-19 vaccination status, we did descriptive analysis and the Chi-square test to examine the data results.
Results
There were 120 respondents in total, which all were processed for the analysis. out of 99 respondents who had full vaccination records. Then, 21 respondents who did not complete their vaccination status or receive the vaccine. Breast cancer is the most common cancer type in this population, which consists of 80 women and 40 males. Then, 59 respondents had increased Il-6 levels, whereas 61 respondents had normal levels. Findings of the research showed no statistically significant relationship between IL-6 levels and vaccination status (p>0.05).
Conclusions
IL-6 levels were used to analyze the relationship between vaccination status and cancer progression, and it was shown that participants who had received immunizations had no more impact on IL-6 levels than those who had not.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rico Alfredo Hutabarat.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06